LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
| Revenue (TTM) | $1.47B |
| Gross Profit (TTM) | $996.85M |
| EBITDA | $260.14M |
| Operating Margin | 13.50% |
| Return on Equity | 15.40% |
| Return on Assets | 5.04% |
| Revenue/Share (TTM) | $26.89 |
| Book Value | $24.07 |
| Price-to-Book | 3.38 |
| Price-to-Sales (TTM) | 3.06 |
| EV/Revenue | 2.929 |
| EV/EBITDA | 20.95 |
| Quarterly Earnings Growth (YoY) | 287.80% |
| Quarterly Revenue Growth (YoY) | 10.80% |
| Shares Outstanding | $54.93M |
| Float | $54.83M |
| % Insiders | 0.42% |
| % Institutions | 113.15% |
Volatility is currently contracting
Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.
LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure.
While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.05 per share a year ago.
GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To lis.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LIVN and any ticker you trade — then tracks every position and per-strategy win rate.
